Results 271 to 280 of about 93,504 (350)

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 337-346, January 2026.
Abstract Aims Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report
Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Requiem for mineralocorticoid blockade in maintenance dialysis. [PDF]

Lancet
Soomro QH, Charytan DM.
europepmc   +1 more source

The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature

American Journal of Nephrology, 2017
Zachary Belden, J. Deiuliis, M. Dobre, S. Rajagopalan   +3 more
semanticscholar   +1 more source

IL‐6 in the spotlight: From cardiovascular pathophysiology to therapy

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Interleukin‐6 (IL‐6) links inflammation to cardiovascular and multi‐organ dysfunction. This review integrates mechanistic, translational, and clinical evidence supporting IL‐6 as both a biomarker and therapeutic target in the continuum of cardiovascular and cardio‐renal disease.
Alberto Preda, Amedeo Tirandi, Giulio Leo, Davide Di Vece, Gemma Vilahur, Aldo Bonaventura, Elena Osto, Stefano Ministrini, Simon Kraler, Petra Kleinbogard, Giovanni Camici, Federico Carbone, Fabrizio Montecucco, Luca Liberale   +13 more
wiley   +1 more source

Mineralocorticoid effects of fludrocortisone and hydrocortisone in primary adrenal insufficiency: EU-AIR patient data. [PDF]

J Endocrinol Invest
Ekman B, Quinkler M, Zhang P, Isidori AM, Murray RD, Wahlberg J, EU-AIR investigators.   +6 more
europepmc   +1 more source

Trained Immunity and Cardiovascular Risk: An Immunological Perspective

Immunological Reviews, Volume 337, Issue 1, January 2026.
ABSTRACT Systemic inflammation is a key driver of atherogenesis and its complications. While anti‐inflammatory therapies targeting pathways such as IL‐1β and IL‐6 have shown promise in established atherosclerotic cardiovascular disease (ASCVD), potential systemic effects raise concerns about immune suppression and infection, underscoring the need for ...
Katherine A. Boden, Jason Chai, Tafadzwa T. J. Kufazvinei, Robin P. Choudhury   +3 more
wiley   +1 more source

Oral Eplerenone for Exudative Retinal Detachment Secondary to Central Serous Chorioretinopathy: A Case Report. [PDF]

Cureus
Paliwal S, Upadhaya P, Thakar S.
europepmc   +1 more source

Screening and Diagnosis of Primary Aldosteronism in Patients Using Renin‐Angiotensin System Inhibitors

The Journal of Clinical Hypertension, Volume 28, Issue 1, January 2026.
ABSTRACT This study investigated whether patients receiving renin‐angiotensin system inhibitors (RASIs) can undergo reliable screening for primary aldosteronism (PA) without discontinuation of therapy. Consecutive patients with hypertension who underwent PA screening at our hospital between 2016 and 2024 while on RASIs were recruited.
Qian Wang, Hui Dong, Hong‐Wu Li, Yu‐Bao Zou, Xiong‐Jing Jiang   +4 more
wiley   +1 more source

Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? [PDF]

Eur Heart J
Packer M.
europepmc   +1 more source

Mineralocorticoid Receptor and Endothelial Dysfunction in Hypertension

Current Hypertension Reports, 2019
Jessica L. Faulkner, Eric J. Belin de Chantemèle   +1 more
semanticscholar   +1 more source